There is no FDA-approved Zepbound pill. Zepbound (tirzepatide) is an injectable medicine, and its prescribing information lists subcutaneous dosage forms, not tablets. Oral medicines for weight management do exist, but they are not oral tirzepatide.
This page previously claimed oral tirzepatide was in phase 3 development and predicted approval in 2027–2028. Those claims were not substantiated and remain removed. This update does not assign a replacement approval date.
Separate the brand, ingredient, and route
| Product | Active ingredient and action | Route relevant to this comparison |
|---|---|---|
| Zepbound | Tirzepatide; GIP and GLP-1 receptor agonist | Subcutaneous injection |
| Wegovy tablets | Semaglutide; GLP-1 receptor agonist | Oral tablet |
| Foundayo tablets | Orforglipron; GLP-1 receptor agonist | Oral tablet |
Wegovy (semaglutide) tablets and Foundayo (orforglipron) have FDA-approved labeling for weight reduction and long-term maintenance in adults with obesity, or overweight with at least one weight-related condition, alongside dietary and activity measures. Their ingredients, administration requirements, and supporting studies differ.
The Zepbound label also includes moderate to severe obstructive sleep apnea in adults with obesity. That indication does not automatically transfer to another medicine because it also supports weight management. Similarly, Wegovy's tablet and injection indications are not identical; check the formulation rather than relying on the brand name alone.
What an oral tirzepatide claim would need to show
A credible phase 3 claim should identify a registered trial, the investigational ingredient, the oral formulation, the sponsor, and the study phase. A trial of injectable tirzepatide is not evidence of an oral program. A trial of orforglipron is not a tirzepatide trial.
This review did not verify an oral tirzepatide phase 3 program. That is not a claim to know every unpublished development project. It means there is no verified basis here for predicting a pill's approval, dose, price, insurance coverage, or launch.
Approval requires a regulatory decision for a particular product and formulation. Search popularity, a seller's listing, a patent, or an ingredient name on a capsule does not establish that decision.
Tablet routines differ
The following summarizes FDA-label administration requirements, not a personalized prescription. Your prescriber determines your medicine and dose. Do not adjust your dose or switch products without consulting them.
| Approved oral product | Administration summary from its label |
|---|---|
| Wegovy tablets | Once daily in the morning on an empty stomach with up to 4 ounces of plain water; at least 30 minutes before food, beverages, or other oral medicines; swallowed whole |
| Foundayo tablets | Once daily with or without food; swallowed whole |
Neither table entry is a dosing conversion from Zepbound. See the Wegovy tablet guide and Foundayo guide for more context, and use the current prescription instructions for your own treatment.
Quick FAQ: Zepbound, Foundayo, and oral Wegovy
Is Zepbound a pill? No. FDA-approved Zepbound contains tirzepatide and is given by subcutaneous injection.
Is Foundayo oral tirzepatide? No. Foundayo is an oral tablet containing orforglipron. It is a different medicine from Zepbound.
Is the Wegovy pill oral tirzepatide? No. Wegovy tablets contain semaglutide. They are neither oral Zepbound nor Foundayo.
Choosing a tablet also does not mean avoiding gastrointestinal effects. Both labels describe nausea and other digestive reactions, including potentially severe reactions. Foundayo has medication-interaction considerations of its own; a pharmacist should review your full list rather than assuming every GLP-1 medicine has the same interactions.
Injection results do not predict an untested pill
A trial result belongs to the product, route, dose, population, duration, and analysis that produced it. Zepbound injection studies cannot establish the effectiveness or safety of an oral tirzepatide product.
Even among approved products, comparing percentages from separate trials is not a head-to-head comparison. Weight-loss averages are not guaranteed individual outcomes. A practical discussion also includes tolerability, the medical reason for treatment, administration routine, and whether the prescribed product can be obtained consistently.
Before paying for a product advertised as oral tirzepatide
Check the exact medicine name, active ingredient, route, and dispensing pharmacy with your prescriber or pharmacist. A product sold as a compounded capsule, liquid, or dissolving preparation is not thereby an FDA-approved Zepbound pill. The approved injection's evidence does not establish equivalent absorption or outcomes for another preparation.
Be cautious about claims of identical results to injections, guaranteed absorption, or a launch date without a regulatory source. Do not use a product labeled for research use as a medicine. If the seller's description conflicts with the prescription or label, resolve that discrepancy before using it.
Questions for a treatment review
- Does the proposed medicine have an indication appropriate to my diagnosis and age?
- Would its daily routine fit my other oral medicines and meals?
- Which side effects or interactions matter with my medical history?
- What is the prescriber's plan for ending one treatment and beginning another?
- Is coverage confirmed for this exact formulation, and what are the ongoing costs?
The Zepbound label does not recommend coadministration with another tirzepatide-containing product or a GLP-1 receptor agonist. Do not add a tablet while continuing injections on your own. There is no milligram-for-milligram conversion between these different ingredients.
If injection technique rather than effectiveness is the problem, ask the pharmacist to review the instructions for your specific device. The Zepbound label includes different presentations, and their handling instructions are not identical. Supplies and disposal arrangements should follow that product's instructions and local sharps rules; a product switch is not the only topic to discuss.
This article is educational and does not replace medical advice. Regulatory and formulation details were checked against the linked prescribing information for this update.
Frequently asked questions
Is there a Zepbound pill?
No FDA-approved Zepbound tablet is listed in the prescribing information reviewed for this September 28, 2026 update. Zepbound contains tirzepatide and is administered by subcutaneous injection.
Is oral tirzepatide in phase 3?
This review did not verify an oral tirzepatide phase 3 program. Earlier claims on this page that such trials were underway and approval was expected in 2027–2028 were unsupported. An injection study or a trial of a different oral drug does not establish an oral tirzepatide program.
Is Foundayo a Zepbound pill?
No. Foundayo contains orforglipron, a GLP-1 receptor agonist. Zepbound contains tirzepatide, a GIP and GLP-1 receptor agonist. They are different medicines, not interchangeable formulations of the same drug.
Are Wegovy tablets oral Zepbound?
No. Wegovy tablets contain semaglutide, while Zepbound contains tirzepatide and is injected. Oral Wegovy, oral Foundayo, and injectable Zepbound are three different FDA-approved products and are not milligram-for-milligram substitutes.
Can you switch from Zepbound to an oral GLP-1?
A prescriber must assess the indication, response, side effects, other medicines, and coverage. There is no milligram-for-milligram conversion from tirzepatide injection to orforglipron or semaglutide tablets. Do not overlap or switch treatments on your own.
